Key result
Higher diastolic BP linked to ~15% higher odds of flecainide modification per 1 mmHg.
Why the study?
Real-world data on flecainide use in older, multimorbid patients remain limited.
Observational (n=31)
No
In a small real-world cohort of older, multimorbid outpatient cardiology patients predominantly with hypertensive heart disease and arrhythmias, flecainide demonstrated acceptable short-term tolerability with no drug-attributable adverse reactions and clinical improvement in two-thirds of patients with follow-up, though nearly one-third required therapy modification.
Answers are grounded in this paper and cite their sources.
Flecainide warrants caution and monitoring in older outpatients; this Level 3 evidence leaves open predictors of tolerability for prospective trials.
Real-world data on flecainide use in older, multimorbid patients remain limited. This retrospective observational study analyzed the electronic medical records of 31 adults prescribed flecainide at a cardiology outpatient clinic (February–May 2025). The cohort was predominantly older (mean age 71.9 ± 9.5 years) and female (71.0%), and most patients had arterial hypertension (83.9%). Therapy modification was required in 32.3% of patients; higher diastolic blood pressure was associated with modification (OR 1.15 per 1 mmHg, 95% CI: 1.01–1.30), but this association was not observed in a complete-case sensitivity analysis. Adverse drug reactions were documented in 12.9% of patients, none of which were attributable to flecainide. Clinical improvement was documented in 14 of 21 patients with follow-up data (66.7%), and therapy modification was associated with lower odds of improvement (adjusted OR 0.046, 95% CI: 0.003–0.618). These exploratory findings suggest acceptable short-term tolerability of flecainide in carefully selected older patients.
No takes yet. Share an insight, caveat, or question.
Getova-Kolarova et al. (2026) conducted an observational in Cardiac arrhythmias and arterial hypertension (n=31). Flecainide was evaluated on Therapy modification required (and association with diastolic blood pressure per 1 mmHg increase) (OR 1.15, 95% CI 1.01-1.30, p=0.038). Flecainide required therapy modification in 32.3% of older outpatients, with higher diastolic blood pressure associated with modification and 66.7% improving.
Synapse has enriched 10 related papers. Consider them for comparative context: